主页 > 医药科学 >
【medical-news】依泽那太加二甲双胍联合治疗可使
The prospective, open-label trial, reported in the July issue of the Journal of Clinical Endocrinology and Metabolism, included 60 women ages 18-40 years with BMI > 27 who were randomized to treatment with extended-release metformin (titrated up to 1000 mg BID), or exenatide (titrated up to 10 g sc BID), or both drugs. Fourteen patients in each treatment arm completed the 24-week trial.
Combination treatment was more effective than monotherapy in improving menstrual cyclicity and ovulation rate and reducing BMI, hyperandrogenism, insulin resistance, and weight, lead author Dr. Karen Elkind-Hirsch, at Woman's Health Research Institute in Baton Rouge, Louisiana and colleagues said.
Specifically, menstrual index increased from 0.29 at baseline to 0.83 after combined therapy, with a corresponding ovulatory rate of 86%. Mean weight loss of 6 kg was accompanied by a mean decrease in abdominal girth of 6 cm.
The authors maintain that while these preliminary findings are promising, "Large, blinded, randomized clinical trials of longer duration are warranted to assess the long-term efficacy and safety of combined exenatide-metformin therapy in overweight women with PCOS."
J Clin Endocrinol Metab 2008;93:2670-2678.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-12-06 17:11
医学,生命科学网